MicroRNA cluster 7/17/155 as a potential driver for high-grade breast tumors transformation through EGFR-associated EMT

Submitted by Anonymous on

BackgroundBreast tumor dedifferentiation and progression onto high-grade states with stem-like fea-tures are governed by complex regulatory networks within t 2 Materials and methods2.1 Microarray datasets collection and differentially expressed mRNAs/miRNAs analysis mRNA expression data were obtained from the Gene Expression...

Impact of antibiotic exposure on survival outcomes in NSCLC patients treated with third-generation EGFR-TKIs

Submitted by Anonymous on

AbstractBackground Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the recommended first-line therapy for advanced EGFR-mutated non-small-cell lung cancer (NSCLC). However, the impact of antibiotic exposure prior to initiating third-generation EGFR-TKIs on treatment efficacy and survival outcomes...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Submitted by Anonymous on

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR-activating mutations. In this phase III, randomized, double-blind trial in China, 336...

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submitted by Anonymous on

Published 25 minutes ago • loading... • Updated 25 minutes ago Show Less Icon Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small...

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 12, 2026-- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib...

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submitted by Anonymous on

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line...

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass., August 12, 2026--The Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy has met its primary endpoint of PFS in a planned interim analysis This is a paid press release. Contact the press release...

Absorption, distribution, metabolism, and excretion of [14C]SH-1028, a third-generation EGFR-TKI, in rats and humans

Submitted by Anonymous on

IntroductionSH-1028 is an irreversible third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) developed for treating locally 1 Introduction Lung cancer is one of the malignant tumors with the highest morbidity and mortality rates worldwide, posing a severe threat to human...

Subscribe to Newsfeed